secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001439222-26-000023
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started
------------------------------------------------------------------------------

- PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.
- Full-year 2025 PYRUKYND revenue $54M; net loss $108M in Q4 vs $96.5M in Q4 2024.
- FDA approved AQVESME (mitapivat) for thalassemia in Dec 2025; U.S. launch began late Jan 2026.
- Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026.
- Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline data in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/0001439222-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001439222-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer